XML 12 R3.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Income Statements - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
 [3]
Profit (loss) [abstract]    
Net sales [1] € 19,889 € 18,360 [2]
Other revenues [1] 1,452 1,529
Cost of sales [1] (5,881) (5,966)
Gross profit [1] 15,460 13,923
Research and development expenses [1] (3,717) (3,335)
Selling and general expenses [1] (4,506) (4,303)
Other operating income [1] 533 563
Other operating expenses [1] (2,476) (1,977)
Amortization of intangible assets [1] (777) (898)
Impairment of intangible assets [1] (210) 371
Fair value remeasurement of contingent consideration [1] (61) (66)
Restructuring costs and similar items [1] (430) (1,060) [2]
Other gains and losses, and litigation [1] (57) (450)
Operating income [1] 3,759 2,768
comprising: Financial expenses [1] (361) (583)
Financial income [1] 184 277
Income before tax and investments accounted for using the equity method [1] 3,582 2,462
Income tax expense [1] (711) (379)
Share of profit/(loss) from investments accounted for using the equity method [1] 85 (22)
Net income from continuing operations [1] 2,956 2,061
Net (income)/loss of the exchanged/held-for-exchange Animal Health business [1] 2,881 202
Net income [1] 5,837 2,263
Net income attributable to non-controlling interests [1] 25 17
Net income attributable to equity holders of Sanofi [1] € 5,812 € 2,246
Average number of shares outstanding [1] 1,225,500,000 1,249,400,000
Average number of shares after dilution (in shares) [1] 1,230,700,000 1,253,800,000
Basic earnings per share from continuing operations [1] € 2.4 € 1.64
Basic earnings per share from discontinued operations [1] 2.34 0.16
Basic earnings per share (in euros per share) [1] 4.74 1.8
Diluted earnings per share from discontinued operations [1] 2.33 0.16
Diluted earnings per share from continuing operations [1] 2.39 1.63
Diluted earnings per share (in euros per share) [1] € 4.72 € 1.79
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.